Objective: To investigate whether artificial removal of zona pellucida (ZP) at the pronuclear stage improves good-quality embryos and blastocyst development in patients with difficulty conceiving because of severe fragmentation in early-cleavage stage.
Design: Exploratory investigation.
Setting: Reproductive center.
Patients: Thirty-four patients scheduled for assisted reproductive technology (ART) treatment in our clinic between February 2020 and January 2021 were selected to undergo ZP removal according to their ART-related medical history. In total, 173 two pronuclei zygotes were obtained, with 101 allocated to the ZP-free group and 72 to the ZP-intact group. All patients had zygotes allocated in both ZP-free and ZP-intact groups.
Interventions: Oocytes that were confirmed to be normally fertilized were placed in sucrose-containing HEPES medium for approximately 5 minutes and cultured under one of the following two conditions: ZP-free, in which the ZP was completely removed from the ooplasm by laser irradiation and a medium-blowing method with a biopsy pipette; and ZP-intact. Subsequently, embryos were either freshly transferred on day 2 (ZP-intact group only, according to patients' wishes), or day 5/6, or they were cryopreserved on day 5/6/7 for future embryo transfer cycles for both groups.
Main outcome measures: Rates of good-quality embryos, blastocyst development, morphologically good-quality blastocyst development, and cryopreservation.
Results: In ZP-free embryos, the inter-blastomere adhesion was not disturbed and the fragmentation was significantly decreased that resulted into significant improvement in all measured parameters compared with the ZP-intact group.
Conclusions: Artificial ZP removal at the pronuclear stage may prevent excessive fragmentation leading to good-quality blastocysts. Moreover, patients with recurrent ART failure may achieve successful pregnancies.
Keywords: ZP-free culture; Zona pellucida; blastocyst development; cytoplasmic fragmentation; human embryo.
© 2024 Published by Elsevier Inc. on behalf of American Society for Reproductive Medicine.